Castle Biosciences Inc. (CSTL)
Castle Biosciences Statistics
Share Statistics
Castle Biosciences has 28.51M shares outstanding. The number of shares has increased by 3.29% in one year.
| Shares Outstanding | 28.51M |
| Shares Change (YoY) | 3.29% |
| Shares Change (QoQ) | 1.81% |
| Owned by Institutions (%) | 94.82% |
| Shares Floating | 27.65M |
| Failed to Deliver (FTD) Shares | 1.52K |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 1.67M, so 5.97% of the outstanding shares have been sold short.
| Short Interest | 1.67M |
| Short % of Shares Out | 5.97% |
| Short % of Float | 6.16% |
| Short Ratio (days to cover) | 4.05 |
Valuation Ratios
The PE ratio is 40.57 and the forward PE ratio is -16.79. Castle Biosciences's PEG ratio is -0.31.
| PE Ratio | 40.57 |
| Forward PE | -16.79 |
| PS Ratio | 2.23 |
| Forward PS | 1.5 |
| PB Ratio | 1.62 |
| P/FCF Ratio | 20.26 |
| PEG Ratio | -0.31 |
Enterprise Valuation
Castle Biosciences has an Enterprise Value (EV) of 646.87M.
| EV / Sales | 1.95 |
| EV / EBITDA | 16.96 |
| EV / EBIT | 9.97 |
| EV / FCF | 17.7 |
Financial Position
The company has a current ratio of 7.29, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.29 |
| Quick Ratio | 7.13 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 0.72 |
| Interest Coverage | 15.03 |
Financial Efficiency
Return on Equity is 4% and Return on Invested Capital is 1.52%.
| Return on Equity | 4% |
| Return on Assets | 3.43% |
| Return on Invested Capital | 1.52% |
| Revenue Per Employee | $436.36K |
| Profits Per Employee | $23.98K |
| Employee Count | 761 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3.32M |
| Effective Tax Rate | 15.39% |
Stock Price Statistics
The stock price has increased by -5.95% in the last 52 weeks. The beta is 0.98, so Castle Biosciences's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -5.95% |
| 50-Day Moving Average | 23.82 |
| 200-Day Moving Average | 26.61 |
| Relative Strength Index (RSI) | 40.61 |
| Average Volume (20 Days) | 450.85K |
Income Statement
In the last 12 months, Castle Biosciences had revenue of 332.07M and earned 18.25M in profits. Earnings per share was 0.66.
| Revenue | 332.07M |
| Gross Profit | 332.07M |
| Operating Income | 8.67M |
| Net Income | 18.25M |
| EBITDA | 38.14M |
| EBIT | 22.14M |
| Earnings Per Share (EPS) | 0.66 |
Balance Sheet
The company has 119.71M in cash and 26.34M in debt, giving a net cash position of 93.36M.
| Cash & Cash Equivalents | 119.71M |
| Total Debt | 26.34M |
| Net Cash | 93.36M |
| Retained Earnings | -200.13M |
| Total Assets | 531.24M |
| Working Capital | 310.76M |
Cash Flow
In the last 12 months, operating cash flow was 64.87M and capital expenditures -28.33M, giving a free cash flow of 36.54M.
| Operating Cash Flow | 64.87M |
| Capital Expenditures | -28.33M |
| Free Cash Flow | 36.54M |
| FCF Per Share | 1.32 |
Margins
Gross margin is 100%, with operating and profit margins of 2.61% and 5.49%.
| Gross Margin | 100% |
| Operating Margin | 2.61% |
| Pretax Margin | 6.49% |
| Profit Margin | 5.49% |
| EBITDA Margin | 11.48% |
| EBIT Margin | 2.61% |
| FCF Margin | 11% |
Dividends & Yields
CSTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.46% |
| FCF Yield | 4.94% |
Analyst Forecast
The average price target for CSTL is $40, which is 97.5% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40 |
| Price Target Difference | 97.5% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 5.48 |
| Piotroski F-Score | 7 |